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Resistant Hypertension
An Overview of Evaluation and Treatment
Pantelis A. Sarafidis, MD, PHD,* George L. Bakris, MD, FAHA, FASN†
Thessaloniki, Greece; and Chicago, Illinois
Resistant hypertension is defined as failure to achieve goal blood pressure (BP) when a patient adheres to the
maximum tolerated doses of 3 antihypertensive drugs including a diuretic. Although the exact prevalence of re-
sistant hypertension is currently unknown, indirect evidence from population studies and clinical trials suggests
that it is a relatively common clinical problem. The prevalence of resistant hypertension is projected to increase,
owing to the aging population and increasing trends in obesity, sleep apnea, and chronic kidney disease. Man-
agement of resistant hypertension must begin with a careful evaluation of the patient to confirm the diagnosis
and exclude factors associated with “pseudo-resistance,” such as improper BP measurement technique, the
white-coat effect, and poor patient adherence to life-style and/or antihypertensive medications. Education and
reinforcement of life-style issues that affect BP, such as sodium restriction, reduction of alcohol intake, and
weight loss if obese, are critical in treating resistant hypertension. Exclusion of preparations that contribute to
true BP treatment resistance, such as nonsteroidal anti-inflammatory agents, cold preparations, and certain
herbs, is also important. Lastly, BP control can only be achieved if an antihypertensive treatment regimen is
used that focuses on the genesis of the hypertension. An example is volume overload, a common but unappreci-
ated cause of treatment resistance. Use of the appropriate dose and type of diuretic provides a solution to over-
come treatment resistance in this instance. (J Am Coll Cardiol 2008;52:1749–57) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.036p
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typertension is the most common chronic disease in
eveloped societies, affecting 25% of adults (1). Meta-
nalyses have demonstrated a linear relationship between
evel of blood pressure (BP) and risk for cardiovascular
vents (2–4). Suboptimal BP control is, consequently, the
ost common attributable risk for death worldwide, being
esponsible for 62% of cerebrovascular disease and 49% of
schemic heart disease as well as an estimated 7.1 million
eaths a year (5).
In the U.S., both the net and age-adjusted prevalence
atios of hypertension continue to increase. Recent data
uggest, however, a slight improvement in hypertension
wareness, treatment, and control (6). The rates of hyper-
ension treatment and control in Europe are much lower
han in the U.S. (7). Several large hypertension outcome
rials also demonstrate a failure to achieve BP goals in spite
f protocol-defined treatment regimens. In these trials, 20%
o 35% of participants could not achieve BP control despite
eceiving 3 antihypertensive medications (8–10) (Fig. 1).
rom the *Section of Nephrology and Hypertension, 1st Department of Medicine,
HEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; and
he †Hypertensive Diseases Unit, Department of Medicine, Section of Endocrinol-
gy, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine,
hicago, Illinois.c
Manuscript received June 20, 2008; revised manuscript received August 18, 2008,
ccepted August 26, 2008.This article provides the clinician with an overview of the
atient characteristics associated with resistant hyperten-
ion, the diagnostic evaluation to assess the problem, and
he treatment strategies for optimizing BP control.
efinition and Prevalence
f Resistant Hypertension
he Joint National Committee 7 defines resistant hyper-
ension as failure to achieve goal BP (140/90 mm Hg for
he overall population and 130/80 mm Hg for those with
iabetes mellitus or chronic kidney disease) when a patient
dheres to maximum tolerated doses of 3 antihypertensive
rugs including a diuretic (11). This definition does not
pply to patients who have been recently diagnosed with
ypertension (12). Moreover, resistant hypertension is not
ynonymous with uncontrolled hypertension. The latter
ncludes all hypertensive patients who lack BP control under
reatment, namely, those receiving an inadequate treatment
egimen, those with poor adherence, and those with unde-
ected secondary hypertension, as well as those with true
reatment resistance. By this definition, patients with resis-
ant hypertension may achieve BP control with full doses of
or more antihypertensive medications (13,14). Although
he definition of resistant hypertension is arbitrary relative
o the number of antihypertensive medications required, the
oncept of resistant hypertension is focused on identifying
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Resistant Hypertension November 25, 2008:1749–57patients who are at high risk of
having reversible causes of hyper-
tension and/or patients who, be-
cause of persistently high BP lev-
els, may benefit from special
diagnostic or therapeutic consid-
erations (13).
The prevalence of resistant hy-
pertension in the general popu-
lation is unknown because of an
inadequate sample size of pub-
lished studies as well as the fea-
sibility of doing a large enough
prospective study that would an-
swer the question (15,16). Small
studies, however, demonstrate a
prevalence of resistant hyperten-
sion that ranges from 5% in
general medical practice to
50% in nephrology clinics (15).
Based on data from the National Health And Nutrition
xamination Survey, 2003 to 2004, 58% of people being
reated for hypertension achieve BP levels140/90 mm Hg
6); control rates among those with diabetes mellitus or
hronic kidney disease are 40% (6,17). In Europe, the
ituation is worse, with control rates among treated hyper-
ensive patients between 19% and 40% in 5 large countries
7). Such data suggest that resistant hypertension is more
ommon than appreciated; however, accurate estimates are
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin-
receptor blocker
BP  blood pressure
CCB  calcium-channel
blocker
eGFR  estimated
glomerular filtration rate
ERA  endothelin-receptor
antagonist
NSAID  nonsteroidal anti-
inflammatory drug
RAS  renin-angiotensin
system
Figure 1 Percent of Patients Reaching JNC-7 BP Goals
Percent of patients reaching the Joint National Committee 7 (JNC-7) blood
pressure (BP) goals in the following trials: ACCOMPLISH (Avoiding Cardiovascu-
lar Events Through Combination Therapy in Patients Living With Systolic Hyper-
tension): amlodipine plus benazepril versus benazepril plus hydrochlorothiazide
(56); INVEST (International Verapamil-Trandolapril Study): verapamil versus
atenolol (10); CONVINCE (Controlled Onset Verapamil Investigation of Cardio-
vascular End Points): verapamil versus atenolol (57); ALLHAT (Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial): chlorthalidone ver-
sus lisinopril versus amlodipine (8); and LIFE (Losartan Intervention For End-
point Reduction in Hypertension Study): losartan versus atenolol (9). Note that,
in all of these trials, more than two-thirds of the patients were receiving at
least 2 antihypertensive agents and about one-third were receiving 3 or more
antihypertensive agents.iot possible, as control rates under treatment are affected by
any factors.
rognosis of Resistant Hypertension
here are no studies specifically powered to address the
rognosis of persons with resistant hypertension. However,
s evident from all population studies on hypertension-
elated target-organ damage, the risks of myocardial infarc-
ion, stroke, heart failure, and renal failure directly relate to
he level of BP (3,11).
These observations coupled with the most common
omorbid conditions seen in patients with resistant hyper-
ension, namely, obesity, diabetes, or chronic kidney disease,
ranslate into an unfavorable prognosis if the BP goal is not
chieved (13). The extent of cardiovascular morbidity and
ortality reduction with achievement of the BP goal has not
een evaluated; however, the benefits are evident by results
f major outcome studies (2,11,18,19).
tiology of “Pseudo-Resistance”
he term “pseudo-resistance” refers to lack of BP control
ith appropriate treatment in a patient who does not have
esistant hypertension. Several factors contribute to elevated
P readings and produce the perception of resistant hyper-
ension (12–16) (Table 1). Such factors include the follow-
ng: 1) suboptimal BP measurement technique; 2) the
hite-coat effect; and 3) poor adherence to prescribed
herapy and other causes described in the following text
13,14). A careful evaluation to exclude these factors before
abeling someone as having resistant hypertension should be
erformed.
Although guidelines to properly assess office BP are
idely available (20), several common mistakes often pro-
uce falsely elevated BP readings. Such mistakes include not
llowing the patient to sit quietly for adequate time, taking
ingle instead of triple readings, using cuffs that are too
mall for the arm, recent smoking, and not fully supporting
he arm at heart level (12,13,16). In older patients, the
resence of heavily calcified or arteriosclerotic arteries that
annot be fully compressed is common and results in
verestimation of intra-arterial BP (12,16).
The “white-coat effect,” defined as an elevation of BP
uring a clinic visit resulting in higher office readings than
t home or ambulatory BP readings (21), is another cause of
seudo-resistance. The white-coat effect is common among
atients with perceived resistant hypertension; 25% of
uch patients referred for resistant hypertension achieve goal
P under treatment when ambulatory measurements are
erformed (22). Patients with apparent resistant hyperten-
ion due to the white-coat effect have less target-organ
amage compared with truly resistant hypertensive patients
23,24). Therefore, such patients should have home or
mbulatory BP measurements (12).
Poor adherence to an adequate antihypertensive regimens another cause of apparent resistant hypertension. Studies
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November 25, 2008:1749–57 Resistant Hypertensionuggest that up to 40% of newly diagnosed hypertensive
atients will discontinue their antihypertensive medications
uring the first year, with only 40% of the remaining
atients continuing their therapy over the next decade
25–27). An evaluation of 4,783 hypertensive patients en-
olled in phase IV clinical studies, with follow-up ranging
rom 30 to 330 days, demonstrated a discontinuation rate of
ntihypertensive drug of 50% within 1 year (28). More-
ver, there was an inverse relationship between the likeli-
ood of early treatment discontinuation and the frequency
f the daily dosing regimen. Factors that improve medica-
ion adherence include the following: 1) selection of agents
ith low side effect profiles such as blockers of the renin-
ngiotensin system (RAS); 2) avoidance of complicated
osing schedules so that once-daily agents either alone or in
xed dose would be preferred; 3) use of pill boxes or family
o help patients with memory deficits or psychiatric disor-
ers; and 4) improved communication between the patient
nd physician to ensure that the patient understands the
egimen and why the medication should be taken in the way
rescribed. Failing to educate the patient about the impor-
ance of achieving BP goals, the predicted side effects of the
gents, and the cost of medication are the most common
easons for drug discontinuation (29,30).
A relatively surprising cause of pseudo-resistant hyper-
ension is suboptimal dosing of antihypertensive agents or
nappropriate combinations of agents. Data from a clinical
ypertension specialty clinic demonstrated that either in-
reasing the dose or initiating or switching to the proper
iuretic was the most common change that achieved BP
oal among patient referred for resistant hypertension (31).
An important culprit that contributes to the genesis of
seudo-resistant hypertension is clinical inertia, defined as
he conscious decision by a clinician to not adequately treat
condition despite knowing that it is present (32). Despite
fforts to translate evidence-based guidelines into clear
ecommendations for clinical practice (11), many physicians
auses of Pseudo-Resistant Hypertension
Table 1 Causes of Pseudo-Resistant Hypertension
Improper blood pressure measurement
Heavily calcified or arteriosclerotic arteries that are difficult to compress (in
elderly persons)
White-coat effect
Poor patient adherence
Side effects of medication
Complicated dosing schedules
Poor relations between doctor and patient
Inadequate patient education
Memory or psychiatric problems
Costs of medication
Related to antihypertensive medication
Inadequate doses
Inappropriate combinations
Physician inertia (failure to change or increase dose regimens when not at goal)re reluctant to adhere to these guidelines (16). Clinicalnertia may be due to lack of training and experience in the
roper use of antihypertensive agents or an overestimation
f care already provided (33). Several studies (34,35) suggest
hat this phenomenon is frequent among American physi-
ians and represents an important culprit working against
he efforts to improve hypertension control rates in the
opulation.
dentification and Reversal
f Pseudo-Resistance Causes
easonable algorithms to identify people with pseudo-
esistant hypertension have been proposed (12,13). In gen-
ral, these approaches adopt a 2-step approach: first, con-
rmation of true resistance (by simultaneous recognition
nd correction of factors related to pseudo-resistance); and
econd, identification of the factors that contribute to
reatment resistance in a given patient (Table 2).
The first step to rule out resistant hypertension is confir-
ation of the diagnosis with reliable office BP readings; the
bserver should strictly follow the relevant BP measurement
uidelines (20). Particular attention should be paid to the
atient’s posture, environment, and triple BP readings with
dequate intervals between. Additionally, use of appropriate
uffs and devices is mandatory. Adherence to the recom-
actors Contributing to Resistant Hypertension
Table 2 Factors Contributing to Resistant Hypertension
Drug-induced
Nonsteroidal anti-inflammatory drugs (including cyclo-oxygenase-2 inhibitors)
Sympathomimetics (decongestants, anorectics)
Cocaine, amphetamines, other illicit drugs
Oral contraceptive hormones
Adrenal steroid hormones
Erythropoietin
Cyclosporine and tacrolimus
Licorice (included in some chewing tobacco)
Over-the-counter dietary and herbal supplements (e.g., ginseng, yohimbine,
ma huang, bitter orange)
Excess alcohol intake
Volume overload
Excess sodium intake
Volume retention from kidney disease
Inadequate diuretic therapy
Associated conditions
Obesity
Diabetes mellitus
Older age
Identifiable causes of hypertension
Renal parenchymal disease
Renovascular disease
Primary aldosteronism
Obstructive sleep apnea
Pheochromocytoma
Cushing’s syndrome
Thyroid diseases
Aortic coarctationIntracranial tumors
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Resistant Hypertension November 25, 2008:1749–57ended BP measurement technique will uncover patients
ho do not meet the definition of resistant hypertension.
Identification of patients who have the white-coat effect
s also important. Either having qualified nonphysician
ersonnel (i.e., nurses) perform office measurements or
sing an automated device with the patient alone in the
oom is useful. Of greater importance, however, is the
etermination of BP levels under treatment with home or
mbulatory measurements, again following relevant recom-
endations (20,36). If BP remains elevated after this
valuation, patient adherence to therapy should be evalu-
ted, as noted earlier.
actors Contributing to Resistant Hypertension
part from the aforementioned variables, a number of
iological or life-style factors can contribute to the devel-
pment of resistant hypertension. Several classes of phar-
acological agents can produce transient or persistent
ncreases in BP (37) (Table 3). Nonsteroidal anti-
nflammatory drugs (NSAIDs) are a common cause of
orsening BP control. They increase BP by an average of 5
m Hg, in part because of inhibition of renal prostaglandin
roduction decreases in renal blood flow, followed by
odium and fluid retention (38). They also interfere with
P-lowering of all antihypertensive drug classes except
tep-by-Step Physician Guide for Evaluation andanagem nt of Pat e ts Appea ing to Haveesistant Hypertension
Table 3
Step-by-Step Physician Guide for Evaluation and
Management of Patients Appearing to Have
Resistant Hypertension
A. Become familiar with and adhere to the most recent hypertension guidelines.
B. Identify and reverse “pseudo-resistance.”
1. Perform proper measurements of BP in the office, following the relevant
guidelines, to confirm the diagnosis of resistant hypertension.
2. Exclude the “white-coat effect” with the use of home or ambulatory BP
measurements.
3. Evaluate patient’s adherence to the treatment regimens; in case of poor
adherence, determine the causes of it. Educate the patient on the risks of
uncontrolled hypertension and the benefits of drug treatment and motivate
the patient to work toward an appropriate BP goal.
4. Closely follow-up nonadherent patients to ensure their compliance.
C. Identify and reverse factors contributing to true resistance.
1. Specifically ask the patient about use of any pharmacological agents that
may increase BP; in case of identification of such a substance, discontinue
or minimize its use.
2. Evaluate the amount of alcohol intake and counsel the patient on the
benefits of ceasing alcohol consumption.
3. Perform a reliable evaluation of dietary salt intake and recommend sodium
restriction to 100 mmol (2.4 g) per day.
4. Assess the degree of obesity, abdominal obesity, and physical activity and
recommend weight reduction and regular aerobic exercise (at least 30 min/
day, most days of the week).
5. Evaluate the level of renal function with estimation of glomerular filtration
rate and modify treatment accordingly.
6. Perform a thorough search for secondary hypertension; if an identifiable cause
is present, treat accordingly or refer the patient to a hypertension center.
D. Treat aggressively with optimal doses of appropriate antihypertensive
medications (including drug combinations) according to patient
characteristics.
E. Refer the patient to a hypertension specialist if BP control is not achieved.oP  blood pressure.alcium antagonists (39,40). The effect of NSAIDs on BP is
ore pronounced in patients with reduced kidney function
13). Selective cyclo-oxygenase-2 inhibitors have effects
imilar to those of NSAIDs on BP control (41). Sympatho-
imetic agents (nasal decongestants, anorectic pills, co-
aine, amphetamine-like stimulants), oral contraceptives,
lucocorticoids, anabolic steroids, erythropoietin, and cyclo-
porine are also commonly used agents that can interfere
ith BP control. Black licorice, included in some oral
obacco products, and herbal supplements (e.g., ma huang
nd ginseng), also raise BP (12,13,16). The effect of these
gents varies; most people manifest little or no effect, but
ertain persons may experience severe BP elevations. Lastly,
llicit drugs can be a major unappreciated cause of resistant
ypertension. Agents such as steroids and cocaine are
ommon causes of resistant hypertension.
Although modest alcohol consumption does not generally
ncrease BP, larger amounts (3 or more drinks/day) have a
ose-related effect on BP, both in hypertensive and normo-
ensive persons (11). Alcohol intake in all hypertensive
atients should be limited to no more than 1 oz of ethanol
day in most men (the equivalent of 2 drinks) and 0.5 oz of
thanol a day in women and lower-weight persons (11).
A key factor responsible for many cases of resistant
ypertension is excess dietary salt intake leading to volume
verload (16). Data from small studies demonstrate that
0% of patients with resistant hypertension have expanded
lasma volume (42). Excessive dietary sodium intake is
idespread in the U.S. and other developed countries, with
rocessed foods being the most common source (13,16).
he majority of patients with resistant hypertension have
igher salt intake than the general population, with an
verage dietary sodium intake exceeding 10 g/day (43).
The optimal way to assess sodium intake is to measure
odium excretion in a 24-h urine collection. Dietary salt
eduction to 3 g/day is associated with modest BP
eductions, which are larger in African-American and el-
erly patients (44). Current guidelines suggest that dietary
odium for a hypertensive person should be 100 mmol/
ay (2.4 g sodium or 6 g sodium chloride) (11). This
uidance is applicable to all patients with resistant hyper-
ension, whereas for salt-sensitive patients, even lower
mounts of sodium may be necessary.
Perhaps the most common unappreciated medical cause
f resistant hypertension is the presence of renal parenchy-
al disease. Kidney disease is the most common secondary
edical cause of hypertension. Failure to appreciate this
elationship may lead to less than optimal choices of
ntihypertensive agents such as failure to use appropriately
osed or selected diuretics based on kidney function. This
ack of diuretic use has been shown in referral practices to be
he primary cause of resistant hypertension, with the use of
hese agents helping to achieve BP goals (31).
Obesity is also a very common feature of patients with
esistant hypertension (45,46). The mechanisms by which
besity contributes to BP elevation and interferes with BP
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November 25, 2008:1749–57 Resistant Hypertensionontrol are complex and not fully understood. Insulin
esistance and hyperinsulinemia, impaired sodium excre-
ion, increased sympathetic nervous system activity, in-
reases in aldosterone sensitivity related to visceral adiposity,
nd obstructive sleep apnea have all been implicated as
otential causes (47–49).
Weight loss achieved with both an appropriate exercise
rogram and a reduced calorie diet is associated with modest
P reductions in obese hypertensive patients (12,13). These
eductions are greater in patients already receiving antihyper-
ensive therapy (50).
Increasing age, namely, 65 years old, is associated with
higher prevalence of resistant hypertension (16,51). In-
reasing age is associated with a higher prevalence of arterial
tiffening, which is not only responsible for falsely elevated
ystolic BP readings but also a major cause of true elevations
11,16). Current guidelines for systolic BP goals of 140 mm
g are more difficult to achieve in patients with isolated
ystolic hypertension (11) and are more difficult with increasing
ge because of the natural history of arteriosclerosis.
Finally, in patients with resistant hypertension, the presence
f secondary hypertension must be considered; although its
revalence is largely unknown, previous studies have shown
hat 5% to 10% of patients with resistant hypertension have
n identifiable cause (52,53). As already mentioned, renal
arenchymal disease must be considered with the strict sense as
he most common medical cause of secondary hypertension
12,16). Renal arterial disease, primary aldosteronism, and
bstructive sleep apnea are other common identifiable causes,
hereas less common forms of secondary hypertension include
heochromocytoma, Cushing’s syndrome, hyperparathyroid-
sm and hypoparathyroidism, aortic coarctation, and intracra-
ial tumors (Table 3). The possibility of an identifiable cause of
ypertension increases with age: renal disease, sleep apnea, and
ossibly primary aldosteronism are more prevalent among
lder patients (13,54).
Patients with documented resistant hypertension should
e evaluated for secondary hypertension if indicated by
linical and routine laboratory evaluation (11). Description
f the signs and symptoms, diagnostic procedures, and
reatment of identifiable causes of hypertension is beyond
he scope of this article (13).
harmacological Treatment
f Resistant Hypertension
uboptimal dosing regimens or inappropriate antihyperten-
ive drug combinations are the most common causes of
esistant hypertension (52,53). Recommendations on the
odification and intensification of antihypertensive regi-
ens for a given patient taking 3 or more drugs is based on
harmacological principles in the context of the underlying
athophysiology that portends hypertension, clinical expe-
ience, and available treatment guidelines.
The present rationale for intervention in resistant hyper-ension (Fig. 2) is to ensure that all possible mechanisms for BP elevation are blocked. As volume expansion seems the
ost frequent pathogenic finding in these patients (42,55),
n appropriate diuretic to decrease volume overload remains
cornerstone of therapy (12,16,56). Studies suggest that
hanges in diuretic therapy (adding a diuretic, increasing the
ose, or changing the diuretic class based on kidney func-
ion) will help 60% of these patients achieve BP goals
12,42,53,55–57). Thiazide diuretics are effective from
oses of 12.5 mg/day given that kidney function is normal;
ncreases up to 50 mg may provide additional BP reduction
n some patients (12). Of note, there are differences between
hiazide and thiazide-type diuretics (13,14,58). A recent
rial comparing hydrochlorothiazide 50 mg and chlorthali-
one 25 mg daily demonstrated that the latter provided
reater ambulatory BP reduction, with the largest difference
ccurring overnight (59). Additionally, a small study of
atients with resistant hypertension demonstrated that
witching from the same dose of hydrochlorothiazide to
hlorthalidone resulted in an additional 8 mm Hg drop in
ystolic BP and increased the number of subjects at goal
60). Unfortunately, chlorthalidone is not commonly avail-
ble in fixed-dose combinations; therefore, its use will
equire separate prescriptions.
The most crucial part of diuretic therapy is to know when
idney function has deteriorated, so that one may select the
roper class of diuretic. For thiazides, this deterioration is
enerally thought to have occurred when the estimated
lomerular filtration rate (eGFR) falls to 50 ml/min/1.73
2; chlorthalidone can still be effective to an eGFR of 40
l/min/1.73 m2 if hypoalbuminemia or hyperkalemia is not
resent. For patients with eGFR 40 ml/min/1.73 m2, a
oop diuretic should be used (12,13,16). Furosemide or
umetanide must be given twice daily, and possibly thrice
aily in some cases, as they have short durations of action of
to 6 h. Thus, once-daily use is associated with intermittent
atriuresis and consequent reactive sodium retention medi-
ted by increases in the RAS (12,16,61). The loop diuretic
orsemide has a longer duration of action and may be given
nce or twice daily (12).
Use of the other drug classes in patients with resistant
ypertension should be based on the general principles of
ombination therapy, namely, inhibition of different patho-
enic mechanisms, choice of drugs that will compensate for
ossible pathophysiological changes evoked by the first
rug, and consideration of compelling indications (11,12).
oreover, the Food and Drug Administration has recently
pproved 3 fixed-dose combination antihypertensive agents
or use as first-line therapy (62). These combinations all
ave an agent that blocks the RAS. Fixed-dose antihyper-
ensive combinations are also very useful for patients with
esistant hypertension, especially for those with adherence
roblems (63,64).
Ultimately, patient characteristics (age, probable patho-
enic mechanisms involved, and concomitant diseases) will
etermine the best combination of agents needed to achieve
P goal. In general, most patients should be on a blocker of
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Resistant Hypertension November 25, 2008:1749–57he RAS along with a calcium antagonist and an appropri-
tely dosed diuretic. In this case, the physician must ensure
hat these agents are prescribed in full dosages, especially for
atients with increased weight, and for appropriate time
ntervals. If BP remains above goal, the next step is to add
fourth agent; a vasodilating beta-blocker is a good choice
f pulse rate is not too low. Peripheral alpha-blockers are
ell tolerated and can be used if the beta-blocker selected
oes not have alpha-blocking activity.
For true resistant hypertension, there are also good data
o support adding a complementary calcium antagonist to a
egimen including a RAS blocker, diuretic, and calcium-
hannel blocker (CCB); for example, adding long-acting
iltiazem to nifedipine XL. Such a combination of comple-
entary CCBs results in additive BP reduction with a low
ide effect profile and makes pharmacological sense (65,66).
Combining an angiotensin-converting enzyme (ACE)
nhibitor with an angiotensin receptor blocker (ARB) does
ot make sense as it was recently shown to be less effective
n terms of BP reduction than was adding a diuretic or a
CB to an ARB (67), was shown not to reduce cardiovas-
ular or renal events to any greater extent than individual
Figure 2 An Approach to Achieving BP Goal in Resistant Hyper
*Refers to chlorthalidone as the diuretic preferred by the guidelines, namely, thiaz
effects than traditional beta-blockers such as atenolol, and also have outcome da
¶Refers to physicians who are board-certified clinical hypertension specialists. BP
RAS  renin-angiotensin system.gents, and may confer increased risk of side effects (68,69). tn a separate trial, the combination of a renin inhibitor
aliskiren) with an ARB was also associated with a small
dditional BP drop (70). Thus, dual RAS blockade is not
ecommended for patients with resistant hypertension.
Aldosterone is also part of the RAS, and specific
lockade of aldosterone should be considered in certain
ettings. Recent studies suggest that adding spironolac-
one or eplerenone to existing antihypertensive regimens for
atients with resistant hypertension who are obese or have
leep apnea provides significant BP reduction (13,71). For
6 patients with uncontrolled BP taking an average of 4
ntihypertensive medications, the addition of spironolac-
one (12.5 to 25 mg daily) resulted in an average 25/12 mm
g reduction after 6 months (72). Reductions in BP were
imilar in patients with and without primary aldosteronism
nd were not predicted by baseline plasma or 24-h urinary
ldosterone, plasma renin activity, or plasma aldosterone/
enin ratio. These data were confirmed by a recent report of
,411 participants in the Anglo-Scandinavian Cardiac Out-
omes Trial—Blood Pressure Lowering Arm who were
nselected for plasma aldosterone and renin activity (73)
nd who received spironolactone as a fourth-line antihyper-
on
e. **Vasodilating beta-blockers such as carvedilol and nebivolol have fewer side
eart disease; therefore, they are suggested for better patient adherence.
d pressure; CCB  calcium-channel blocker; CKD  chronic kidney disease;tensi
ide-lik
ta on h
 blooensive agent for uncontrolled BP in addition to an average
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November 25, 2008:1749–57 Resistant Hypertensionf 3 drugs. Use of spironolactone resulted in a BP drop of
1.9/9.5 mm Hg that was unaffected by age, sex, smoking,
nd diabetic status. Breast tenderness with spironolactone is
ommon at doses above 25 mg/day but can be avoided with
he use of the more selective mineralocorticoid receptor
ntagonist, epleronone (14). Epleronone also has demon-
trated BP-lowering efficacy as well as benefits on kidney
isease progression (74).
Amiloride is another potassium-sparing diuretic associ-
ted with BP reductions in patients with resistant hyper-
ension (75). When physicians prescribe these agents, espe-
ially in combination with an ACE inhibitor or an ARB,
hey should monitor potassium levels closely if kidney
unction is not within the normal range, and educate the
atient to avoid food and supplements rich in potassium, as
yperkalemia is a potentially dangerous side effect (14,76).
If BP control is still not achieved with full doses of a
-drug combination, use of other agents such as centrally-
cting alpha-agonists (methyldopa and clonidine) or vaso-
ilators (hydralazine or minoxidil) is needed. These agents
re very effective for lowering BP, but have poor tolerability
nd lack of positive outcome data (11). It must be noted,
owever, that if therapy has progressed to adding a fourth
gent, referral to a clinical hypertension specialist is war-
anted (33).
Another class of agents that may prove useful for resistant
ypertension is endothelin-receptor antagonists (ERAs). In
atients with mild-to-moderate essential hypertension, both
onselective and selective (type A receptor) ERAs produce
P reductions comparable to those of common antihyper-
ensive agents (77), but concerns about adverse events
recluded their use as a treatment option for uncomplicated
ypertension (78). However, darusentan, a selective ERA
ecently tested in 115 patients with resistant hypertension,
emonstrated a dose-dependent decrease in BP. The largest
eductions (11.5/6.3 mm Hg) were observed after 10 weeks
f follow-up with the largest dose, and the drug was
enerally well tolerated (78). Ongoing phase III clinical
rials with such agents are awaited to provide further
nformation in this interesting field.
onclusions
lthough the number of patients who cannot achieve BP
oals on a regimen of multiple medications is growing, the
henomenon of resistant hypertension is widely understud-
ed, a fact that requires treatment recommendations be
ased on pathophysiological principles and clinical experi-
nce. Effective management of resistant hypertension re-
uires, first, a careful examination for and exclusion of
actors associated with pseudo-resistance, and second, iden-
ification and, when possible, modification of factors related
o true BP elevations. After all of these are successfully
anaged, an aggressive treatment regimen designed to
ompensate for all mechanisms of BP elevation in a given
atient, most importantly to control volume overload withroper use of diuretics, will help in moving toward effective
P control for the majority of patients.
eprint requests and correspondence: Dr. George L. Bakris,
ypertensive Diseases Unit, University of Chicago Pritzker
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